EMA Recommends Granting a Marketing Authorisation for Catumaxomab By Ogkologos - November 12, 2024 672 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the intraperitoneal treatment of malignant ascites Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR 5-Year-Old Boy Surprised With Paycheck For Helping Electrical Company Fix His... January 21, 2022 ESMO Launches Living Guidelines to Enhance the Usability of its Clinical... May 10, 2023 Cervical screening in Wales extended to every 5 years: Why the... January 7, 2022 EMA Recommends Extension of Therapeutic Indications for Durvalumab and Adopts a... December 23, 2022 Load more HOT NEWS Presence of Intratumoural TLSs in Advanced STS as a Potential Predictive... FDA Approves Osimertinib for Locally Advanced, Unresectable Stage III Non-Small Cell... A Painful Breast Lump May Be Mistaken For Cancer When It’s... Sacituzumab Govitecan Demonstrates a Relatively High ORR with Rapid Responses in...
